LGALS9 and acute myeloid leukemia: Furthermore, patient-derived AML cells that did not respond to AraC were eliminated by Gal-9 in a dose-dependent manner to a similar extent as samples that were sensitive to AraC (Fig. 6E, F and Supplementary Fig. 5E, F).